Abstract
Mitotane (o,p'-DDD; Lysodren) is the drug most commonly used to treat dogs with pituitary-dependent hyperadrenocorticism. Although variations of the original protocol, suggested more than 20 years ago, have been reported, most clinicians still use an initial loading dose of mitotane followed by a weekly maintenance dose. Although a gratifying response to treatment is seen in most dogs, some dogs are neither easy nor straightforward to treat and present the practitioner with one or more therapeutic challenges, including failure to respond adequately, development of adverse effects, or development of relapse during treatment. Nevertheless, with careful management and follow-up, such problems can be overcome and a successful outcome achieved in most cases.
MeSH terms
-
Adrenal Cortex Diseases / complications
-
Adrenal Cortex Diseases / drug therapy
-
Adrenal Cortex Diseases / veterinary*
-
Adrenocortical Hyperfunction / drug therapy
-
Adrenocortical Hyperfunction / metabolism
-
Adrenocortical Hyperfunction / veterinary*
-
Animals
-
Antineoplastic Agents, Hormonal / adverse effects
-
Antineoplastic Agents, Hormonal / pharmacology
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Diabetes Complications
-
Diabetes Mellitus / metabolism
-
Diabetes Mellitus / veterinary
-
Dog Diseases / drug therapy*
-
Dog Diseases / metabolism
-
Dogs
-
Dose-Response Relationship, Drug
-
Hydrocortisone / blood
-
Hydrocortisone / metabolism
-
Mitotane / adverse effects
-
Mitotane / pharmacology
-
Mitotane / therapeutic use*
-
Polyuria / complications
-
Polyuria / metabolism
-
Polyuria / veterinary
Substances
-
Antineoplastic Agents, Hormonal
-
Mitotane
-
Hydrocortisone